Home>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Crenolanib (CP-868596)

Crenolanib (CP-868596) Sale

(Synonyms: [1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺,CP-868596;CP 868596;CP868596) 目录号 : GC14906

An inhibitor of PDGFRα/β and FLT3

Crenolanib (CP-868596) Chemical Structure

Cas No.:670220-88-9

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥956.00
现货
5mg
¥840.00
现货
25mg
¥2,499.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Cell experiment [1,2]:

Cell lines

EOL-1 cell line, BaF3 cells, H1703 non-small cell lung cancer cell line

Preparation method

The solubility of this compound in DMSO is >22.2mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

50 nM, 48 h

Applications

In EOL-1 cell line derived from a patient with chronic eosinophilic leukemia and expressed the constitutively activated FIP1L1-PDGFRα fusion kinase, Crenolanib inhibited the kinase activity of the fusion oncogene with IC50 of 21 nM. Crenolanib inhibited the proliferation of EOL-1 cells with IC50 of 0.2 pM. Crenolanib inhibited the activation of V561D or D842V-mutant kinases expressed in BaF3 cells with IC50 of 85 nM or 272 nM, respectively. Crenolanib inhibited PDGFRα activation in H1703 non-small cell lung cancer cell line which has 24-fold amplification of the 4q12 region that contained the PDGFRα locus, with IC50 of 26 nM. Crenolanib (50 nM) decreased A549 NSCLC cell viability, induced apoptosis in A549 NSCLC cells, and inhibited cell migration in A549 NSCLC cells.

Animal experiment [2]:

Animal models

A549 cells xenograft mouse model

Dosage form

10 mg/kg and 20 mg/kg, 2 weeks

Application

Crenolanib (10 mg/kg and 20 mg/kg) suppressed non-small-cell lung cancer tumor growth and induced tumor cell apoptosis, and the dosage of crenolanib applied was well tolerated by recipient mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Heinrich M C, Griffith D, McKinley A, et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors[J]. Clinical cancer research, 2012, 18(16): 4375-4384.

[2]. Wang P, Song L, Ge H, et al. Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo[J]. OncoTargets and therapy, 2014, 7: 1761.

产品描述

Crenolanib (CP-868596) is a potent, specific, and orally available inhibitor of PDGFRα, PDGFRβ and FLT3 with inhibitor-binding constant (Kd) of 3.2, 2.1, and 0.74 nM, respectively [1].

It has been shown that crenolanib is more potent than quizartinib and sorafenib at blocking FLT3 autophosphorylation and causing cytotoxicity [2]. Crenolanib is confirmed to be100-fold more potent than imatinib at suppressing D842V mutation. In addition, it has been reported that crenolanib inhibits PDGFRα D842V mutation rather than V561D mutation, with IC50 value of 10 nM [1]. In EOL-1 cells, crenolanib also inhibits the FIP1L1-PDGFRA fusion kinase activity (IC50=1 nM) and cell proliferation (IC50= 0.2 pM)[1].

References:
[1] Heinrich MC1, Griffith D, McKinley A, Patterson J, Presnell A, Ramachandran A, Debiec-Rychter M.

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res. 2012 Aug 15;18(16):4375-84.

[2] Galanis A1, Ma H, Rajkhowa T, Ramachandran A, Small D, Cortes J, Levis M. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. Blood. 2014 Jan 2;123(1):94-100.

Chemical Properties

Cas No. 670220-88-9 SDF
别名 [1-[2-[5-(3-甲基氧杂环丁烷-3-基甲氧基)苯并咪唑-1-基]喹啉-8-基]哌啶-4-基]胺,CP-868596;CP 868596;CP868596
化学名 1-[2-[5-[(3-methyloxetan-3-yl)methoxy]benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine
Canonical SMILES CC1(COC1)COC2=CC3=C(C=C2)N(C=N3)C4=NC5=C(C=CC=C5N6CCC(CC6)N)C=C4
分子式 C26H29N5O2 分子量 443.54
溶解度 ≥ 22.2mg/mL in DMSO, ≥ 2.5 mg/mL in EtOH with ultrasonic 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.2546 mL 11.2729 mL 22.5459 mL
5 mM 0.4509 mL 2.2546 mL 4.5092 mL
10 mM 0.2255 mL 1.1273 mL 2.2546 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置